Myasthenia gravis: Another autoimmune disease associated with hepatitis C virus infection

Digestive Diseases and Sciences

Volumn 44, Issue 1, 1999, Pages 186-189

  Eddy, Setijoso ^a   Wim, Robberecht ^a   Peter, Van Eycken ^a   Tanja, Roskams ^a   Jan, Tack ^a   Werner, Van Steenbergen ^a,b  

^a Department of Neurology   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acetylcholine receptor; Autoimmune diseases; Hepatitis C; Molecular mimicry; Myasthenia gravis

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR; PYRIDOSTIGMINE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CROSS REACTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MALE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION DISORDER; PREVALENCE; PRIORITY JOURNAL;

AUTOANTIBODIES; CHOLINESTERASE INHIBITORS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; PYRIDOSTIGMINE BROMIDE; RECEPTORS, CHOLINERGIC;

EID: 0032920783     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026683007277     Document Type: Article

References (33)

1. 1. Phillips LH: The epidemiology of myasthenia gravis. Neurol Clin North Am 12:263-271, 1994
2. 2. Drachman DB: Myasthenia gravis. N Engl J Med 330:1797-1810, 1994
3. 3. Hopkins LC: Clinical features of myasthenia gravis. Neurol Clin North Am 12:243-261, 1994
4. 4. Richman DP, Agius MA: Acquired myasthenia gravis. Neurol Clin North Am 12:273-284, 1994
5. 5. Berrih-Aknin S: Myasthenia gravis, a model of organ-specific autoimmune disease. J Autoimmun 8:139-143, 1995
6. 6. Vincent A: Aetiological factors in development of myasthenia gravis. Adv Neuroimmunol 4:355-371, 1994
7. 7. Stefansson K, Dieperink ME, Richman DP, Gomez CM, Marton LS: Sharing of antigenic determinants between the nico-tinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. N Engl J Med 312:221-225, 1985
8. 8. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MBA: Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alfa-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 84:1174-1180, 1989
9. 9. Verma A, Berger JR: Myasthenia gravis associated with dual infection of HIV and HTLV-I. Muscle Nerve 18:1355-1356, 1995
10. 10. Authier F-J, De Grissac N, Degos J-D, Gherardi RK: Transient myasthenia gravis during HIV infection. Muscle Nerve 18:914-916, 1995
11. 11. Strassburg CP, Obermayer-Straub P, Manns MP: Autoimmunity in hepatitis C and D virus infection. J Viral Hepatitis 3:49-59, 1996
12. 12. Pawlotsky J-M, Ben Yahia M, Andre C, et al: Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 19:841-848, 1994
13. 13. Picollo G, Franciotta D, Versino M, Alfonsi E, Lombardi M, Poma G: Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alfa treatment. J Neurol Neurosurg Psych 60:348, 1996
14. 14. Mase G, Zorzon M, Biasutti E, Vitrani B, Cazzato G, Urban F, Frezza M: Development of myasthenia gravis during interferon-alfa treatment for anti-HCV positive chronic hepatitis. J Neurol Neurosurg Psychiatry 60:348-349, 1996
15. 15. Quilichini R, Mazzerbo F, Baume D, Amiel O, Lafeuillade A, Pellegrino P: Myasthénie au cours d'un traitement par l'interféron alpha. Presse Med 24:1178, 1995
16. 16. Vincent A: Acetylcholine receptor autoantibodies. In Autoantibodies. JB Peter, Y Shoenfield (eds). Amsterdam, Elsevier Science BV, 1996, pp 1-9
17. 17. Reyes H: Striational autoantibodies. In Autoantibodies. JB Peter, Y Shoenfield (eds). Amsterdam, Elsevier Science BV, 1996, pp 805-809
18. 18. Yap SH, Willems M, Van den Oord J, Habets W, Middeldorp JM, Hellings JA, Nevens F, Moshage H, Desmet V, Fevery J: Detection of hepatitis C virus antigen by immunohistochemical staining: A histological marker of hepatitis C virus infection. J Hepatol 20:275-281, 1994
19. 19. Booth JCL, Thomas HC: Pathogenesis of chronic hepatitis C and associated clinical manifestations. Bailliere's Clin Gastroenterol 10:257-274, 1996
20. 20. Colombo M: The natural history of hepatitis C. Bailliere's Clin Gastroenterol 10:275-288, 1996
21. 21. Obermayer-Strauss P, Manns MP: Cytochromes P-450 and UDP-glucuronosyltransferases as hepatocellular autoantigens. Bailliere's Clin Gastroenterol 10:501-532, 1996
22. 22. Michel G, Ritter A, Gerken G, Meyer Zum Büschenfelde KH, Decher G, Manns M: Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 339:267-269, 1992
23. 23. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F: Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 104:1762-1767, 1993
24. 24. Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y, Valla D, Borotto E, Yamamoto AM, Huraux JM, Opolon P, Homberg JC: Liver:kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 16:630-636, 1992
25. 25. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, Decastro M, Mateos FG, Vicario JL, Balas A, Moreno-Otero R: Latent autoimmune hepatitis triggered during Interferon therapy in patients with chronic hepatitis C. Gastroenterology 108:1770-1777, 1995
26. 26. Shindo M, Di Bisceglie AM, Hoofnagle JH: Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 102:1406-1408, 1992
27. 27. Ruiz-Moreno M, Rua MJ, Carreno V, Quiroga JA, Manns M, Meyer zum Büschenfelde KH: Autoimmune chronic hepatitis C type 2 manifested during interferon therapy in children. J Hepatol 12:265-266, 1991
28. 28. Renault PF, Hoofnagle JH: Side effects of alpha interferon. Semin Liver Dis 9:273-277, 1989
29. 29. Marcellin P, Pouteau M, Renard P, Grynblat JM, Colas Linhart N, Bardet P, Bok B, Benhamou JP: Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 33:855-856, 1992
30. 30. Marcellin P, Pouteau M, Messian O, Bok B, Erlinger S, Benhamou JP: Virus de l'hépatite C, interféron alpha et dysthyroïdie. Gastroenterol Clin Biol 17:887-891, 1993
31. 31. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, Moreno-Otero R: Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol 44:635-642, 1996
32. 32. Peters M: Mechanisms of action of Interferons. Semin Liver Dis 9:235-239, 1989
33. 33. Tilg H: New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112:1017-1021, 1997